NYSEAMERICAN:MTNB Matinas BioPharma (MTNB) Stock Price, News & Analysis $3.71 -0.13 (-3.39%) (As of 09/16/2024 ET) Add Compare Share Share Today's Range$3.40▼$3.8850-Day Range N/A52-Week Range$3.28▼$44.50Volume50,254 shsAverage Volume28,582 shsMarket Capitalization$18.62 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Matinas BioPharma alerts: Email Address Matinas BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.1% Downside$3.00 Price TargetShort InterestHealthy1.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 stars 1.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMatinas BioPharma has received no research coverage in the past 90 days.Read more about Matinas BioPharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.18% of the float of Matinas BioPharma has been sold short.Short Interest Ratio / Days to CoverMatinas BioPharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas BioPharma has recently decreased by 95.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MTNB. Previous Next 3.5 News and Social Media Coverage News SentimentMatinas BioPharma has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Matinas BioPharma this week, compared to 1 article on an average week.Search Interest6 people have searched for MTNB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Matinas BioPharma is held by insiders.Percentage Held by InstitutionsOnly 11.77% of the stock of Matinas BioPharma is held by institutions.Read more about Matinas BioPharma's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas BioPharma is -30.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas BioPharma is -30.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas BioPharma has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now. About Matinas BioPharma Stock (NYSEAMERICAN:MTNB)Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.Read More MTNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTNB Stock News HeadlinesSeptember 8, 2024 | americanbankingnews.comMatinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Up to $3.64September 3, 2024 | benzinga.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Insider Trading ActivitySeptember 16, 2024 | Crypto 101 Media (Ad)The #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. August 30, 2024 | uk.investing.comMatinas BioPharma enacts reverse stock splitAugust 25, 2024 | nz.finance.yahoo.comMatinas BioPharma Holdings Inc (6LJ.DU)August 17, 2024 | markets.businessinsider.comBuy Rating Affirmed: Matinas BioPharma’s Solid Financials and Promising Drug DevelopmentAugust 15, 2024 | msn.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateSeptember 16, 2024 | Crypto 101 Media (Ad)The #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. August 14, 2024 | markets.businessinsider.comMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024August 14, 2024 | globenewswire.comMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 7, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024June 24, 2024 | globenewswire.comMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramJune 13, 2024 | globenewswire.comMatinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.May 16, 2024 | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | globenewswire.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateSee More Headlines Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:MTNB CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside-19.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,940,000.00 Net MarginsN/A Pretax Margin-2,093.25% Return on Equity-120.50% Return on Assets-92.69% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual Sales$1.10 million Price / Sales16.93 Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book0.84Miscellaneous Outstanding Shares5,020,000Free Float226,738,000Market Cap$18.62 million OptionableNot Optionable Beta1.65 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Jerome D. Jabbour J.D. (Age 50)Co-Founder, CEO, President & Director Comp: $842.38kDr. Theresa Matkovits Ph.D. (Age 57)Chief Development Officer Comp: $570.08kDr. James J. Ferguson FACC (Age 70)M.D., Chief Medical Officer Comp: $621kMr. Keith A. Kucinski CPA (Age 54)M.B.A., Chief Financial Officer Comp: $249.05kDr. Hui Liu M.B.A. (Age 56)Ph.D., Chief Technology Officer Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply ChainMr. Thomas J. Hoover M.B.A. (Age 54)Chief Business Officer More ExecutivesKey CompetitorsLeap TherapeuticsNASDAQ:LPTXEupraxia PharmaceuticalsNASDAQ:EPRXPrecision BioSciencesNASDAQ:DTILSELLAS Life Sciences GroupNASDAQ:SLSRAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInstitutional OwnershipHighbridge Capital Management LLCBought 10,644,331 shares on 8/12/2024Ownership: 4.244%Sargent Investment Group LLCSold 118,500 shares on 8/10/2024Ownership: 1.392%Towercrest Capital ManagementBought 1,886,715 shares on 8/6/2024Ownership: 0.752%Alliance Wealth Management GroupBought 1,886,715 shares on 7/12/2024Ownership: 0.752%View All Institutional Transactions MTNB Stock Analysis - Frequently Asked Questions How have MTNB shares performed this year? Matinas BioPharma's stock was trading at $0.2801 at the start of the year. Since then, MTNB stock has increased by 1,224.5% and is now trading at $3.71. View the best growth stocks for 2024 here. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). Who are Matinas BioPharma's major shareholders? Matinas BioPharma's top institutional investors include Highbridge Capital Management LLC (4.24%), Sargent Investment Group LLC (1.39%), Towercrest Capital Management (0.75%) and Alliance Wealth Management Group (0.75%). View institutional ownership trends. How do I buy shares of Matinas BioPharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas BioPharma investors own include KushCo (KSHB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX) and Organigram (OGI). This page (NYSEAMERICAN:MTNB) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTNB Stock Alerts